Healthcare / Medical DevicesNYSE American
$3.66
-0.28 (-7.11%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-72.7M · quality 69.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$417M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-49.8%
↓Gross Margin
N/A
•Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2011–2025 · 14 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.92x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-103.1M · FCF $-95.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||
| Revenue | — | — | — | — | $10.8M | — | — | — | $5.9M | $4.8M | $4.8M | — | — | — | — | — |
| Net Income | $-103.1M | $-103.1M | $-79.3M | $-46.5M | $-7.3M | $-3.4M | $-3.4M | $-5.1M | $-6.7M | $-6.2M | $-4.7M | $-3.7M | $-6.0M | $-3.9M | $-3.5M | $-2.8M |
| EBITDA | $-100.8M | $-100.8M | $-78.1M | $-39.0M | $-7.1M | — | — | — | — | $-6.2M | $-4.6M | $-3.8M | $-3.9M | $-3.3M | $-2.8M | $-2.1M |
| EPS | -1.40 | -1.40 | -1.23 | -1.74 | -0.50 | -0.30 | -0.50 | — | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | 42.8% | — | — | — | 31.1% | 17.6% | 2.7% | — | — | — | — | — |
| Operating Margin | — | — | — | — | -68.5% | — | — | — | -113.6% | -132.5% | -106.6% | — | — | — | — | — |
| Net Margin | — | — | — | — | -67.4% | — | — | — | -113.1% | -129.4% | -98.8% | — | — | — | — | — |
| Balance Sheet | ||||||||||||||||
| Debt/Equity | 0.02 | 0.02 | 0.01 | 0.03 | 0.01 | — | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 8.74 | 8.74 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||
| Free Cash Flow | $-95.2M | $-95.2M | $-72.7M | $-38.0M | $-8.0M | $-3.2M | $-3.9M | $-5.5M | $-6.0M | $-6.3M | $-4.4M | — | — | $-3.1M | $-2.5M | $-2.6M |
| Returns | ||||||||||||||||
| ROE | -49.8% | -49.8% | -27.3% | -61.9% | -11.9% | -5.0% | -60.2% | -67.0% | -133.2% | -58.1% | -28.7% | -17.7% | -24.9% | -71.9% | -60.0% | -44.0% |
| Valuation | ||||||||||||||||
| P/B | 1.30 | 1.30 | 0.78 | 2.21 | 0.67 | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||
| Revenue Growth | — | — | — | — | — | — | — | — | 24.4% | -0.2% | — | — | — | — | — | — |
| EPS Growth | -13.8% | -13.8% | 29.3% | -248.0% | — | 40.0% | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+42.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.23 → -1.40
Residual
+42.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.